Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Low-grade NMIBC”

11 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 11 results

Large-scale testing (Phase 3)Looking for participantsNCT07804056
What this trial is testing

Investigate the Efficacy and Safety of Alpha1H as a Neoadjuvant Therapy in Participants With Low- to Intermediate-Risk/Low-Grade Papillary Non-Muscle Invasive Bladder Cancer

Who this might be right for
Urinary Bladder NeoplasmsNon-muscle Invasive Bladder Cancer (NMIBC)
Hamlet Pharma AB 194
Testing effectiveness (Phase 2)Study completedNCT03558503
What this trial is testing

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 63
Testing effectiveness (Phase 2)Study completedNCT03081858
What this trial is testing

Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer

Who this might be right for
Bladder Cancer Cell TransitionalNon-Muscle Invasive Bladder CancerBladder Cancer+7 more
Lipac Oncology LLC 15
Large-scale testing (Phase 3)Study completedNCT05136898
What this trial is testing

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 8
Large-scale testing (Phase 3)Active Not RecruitingNCT06331299
What this trial is testing

UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 99
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06227065
What this trial is testing

Precise Chemoresection in Low-grade NMIBC Using Drug Screens in Patient-derived Organoids

Who this might be right for
Bladder CancerNon-muscle Invasive Bladder CancerLow Grade
Hospital Centre Biel/Bienne 28
Large-scale testing (Phase 3)Ended earlyNCT04688931
What this trial is testing

UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 282
Not applicableStudy completedNCT02075060
What this trial is testing

Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer

Who this might be right for
Non Muscle-invasive Bladder Cancer
Poitiers University Hospital 60
Large-scale testing (Phase 3)Active Not RecruitingNCT05243550
What this trial is testing

Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Bladder CancerUrothelial CarcinomaUrothelial Carcinoma Bladder
UroGen Pharma Ltd. 240
Testing effectiveness (Phase 2)Looking for participantsNCT06995677
What this trial is testing

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

Who this might be right for
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc 90
Testing effectiveness (Phase 2)Looking for participantsNCT06637423
What this trial is testing

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Who this might be right for
Non-Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 32